N/A N=16 Web-Based Cognitive Behavioral Stress Management for Latino Sexual Minority Men Living With HIV and Cancer
HIV/AIDS · Cancer
Primary: Change in General Stress — -1.8 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=30 A Research Study Investigating Nonacog Beta Pegol (N9-GP) for Treatment and Prevention of Bleedings in Chinese People With Haemophilia B
Haemophilia B
Primary: Haemostatic Effect of Nonacog Beta Pegol When Used for Treatment of Bleeding Episodes During on Demand and Prophylaxis (PPX) — 203; 3; 26; 8 Bleeding Episodes
N/A N=38 Geniculate Artery Embolization for Treatment of Osteoarthritis
Osteoarthritis
Primary: Percentage Change in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) - Pain Score — -50.1 Percentage change
Phase 1 N=27 CampETEC Hyperimmune Bovine Colostrum (HBC)
Healthy Volunteer
Primary: Incidence of Adverse Events — 1; 1; 0; 1 events
N/A N=17 Task Augmentation of Transcranial Magnetic Stimulation (TMS)
Healthy
Primary: Sternberg Sorting Task (SST) at Baseline — 0.85; 0.64; 0.87; 0.66 proportion of correct responses — p=0.024
N/A N=6,125 Lung Cancer Screening Eligibility Assessment
Lung Cancer
Primary: Full Survey Completion — 358; 381; 383; 389 Participants
N/A N=100 A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
Migraine Headache, Episodic
Primary: Change in Number of Monthly Migraine Headache Days — -3.5; -1.1 migraine days
Phase 2 N=590 Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
RET-altered Non Small Cell Lung Cancer · Medullary Thyroid Cancer · RET-altered Papillary Thyroid Cancer
Primary: Phase 1 : Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of Pralsetinib — 400; 400 mg
N/A N=200 A Prospective, Multi-Center Evaluation of Corneal Flap Creation Using Cheetah Femtosecond Laser System and Cheetah Patient Interface
Refractive Error
Primary: Stromal Bed Surface Quality — 0; 175 Eyes
Phase 3 N=13 Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia
Familial Hypercholesterolemia - Homozygous
Primary: Percentage Change in LDL-C From Baseline to Day 330 (Part 1/Year 1) — -21.6; 11.7 percent change in LDL-C
N/A N=21 DailyDose Smart Snack Study for T1D on MDI
Type 1 Diabetes Mellitus With Hypoglycemia
Primary: Probability of Overnight Hypoglycemia — 23.6; 26.0 percentage of nights
N/A N=299 Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
Lung Cancer
Primary: Body Mass Index (BMI): All Asian Participants — 22.6; 23.1; 26.4 Kilogram per square meter
N/A N=44 Amped-PD: Amplifying Physical Activity Through Music in Parkinson Disease
Parkinson Disease
Primary: Physical Activity Based on the Amount of Moderate Intensity Walking — 9.45; 16.17 minutes of moderate intensity walking
Phase 2 N=35 Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia
Acute Myeloid Leukemia · AML
Primary: Safety and Tolerability of Experimental Dose of Palbociclibin Combination With CPX-351 as Measured by Number of Participants With Dose Limiting Toxicities. — 0…
N/A N=329 Anthropometric and US-Guided Difficult Intubation Prediction With ML Models
Difficult Endotracheal Intubation · Artificial Intelligence
Primary: Support Vector Machine Algorithm Percentage of Accuracy in Predicted Difficult Intubations — 89.39; 77.27; 87.88; 80.30 percentage of estimate